FierceBiotech
@FierceBiotech
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
加入 December 2008
615 正在關注 102.7K 粉絲
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates.
